Haisco Pharmaceutical's non-public share issuance clears SZSE review

Haisco Pharmaceutical Group Co., Ltd. announced on December 19, 2025, that its application for a non-public issuance of shares to specific objects passed the Shenzhen Stock Exchange (SZSE) review. The SZSE listing review center deemed it compliant with issuance conditions, listing conditions, and information disclosure requirements.

Following this approval, the SZSE will submit the application to the China Securities Regulatory Commission (CSRC) to proceed with the registration process. The company emphasized that the implementation of this non-public issuance is contingent upon receiving the CSRC's consent for registration.

There remains uncertainty regarding whether the CSRC will ultimately grant the approval and the timing of such a decision. Haisco Pharmaceutical Group stated it will provide timely disclosures on the progress and advises investors to exercise caution.